Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
about
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@ast
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@en
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@nl
type
label
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@ast
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@en
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@nl
prefLabel
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@ast
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@en
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@nl
P50
P356
P1433
P1476
Extracorporeal Elimination of ...... istant Ovarian Cancer Patients
@en
P2093
Daniel Diaz-Garcia
P356
10.14712/18059694.2015.84
P407
P577
2015-01-01T00:00:00Z